Go Pro
NASDAQ:PTPI

Petros Pharmaceuticals (PTPI) Stock Price, News & Analysis

Petros Pharmaceuticals logo
$0.0035 0.00 (-10.26%)
As of 10:57 AM Eastern

About Petros Pharmaceuticals Stock (NASDAQ:PTPI)

Advanced

Key Stats

Today's Range
$0.0035
$0.0035
50-Day Range
N/A
52-Week Range
$0.00
$0.03
Volume
5,284 shs
Average Volume
110,059 shs
Market Capitalization
$109.06 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.

Receive PTPI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Petros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PTPI Stock News Headlines

Petros Pharmaceuticals Delays Annual 10-K Filing
Someone just dumped the biggest gold fund.
Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing total outflows to 14 billion. At the same time, the World Gold Council recorded the highest quarterly central bank gold buying on record, with buyers taking physical delivery instead of paper shares.tc pixel
Petros Pharmaceuticals Inc (PTPI) - Investing.com
See More Headlines

PTPI Stock Analysis - Frequently Asked Questions

Petros Pharmaceuticals' stock was trading at $0.0071 at the start of the year. Since then, PTPI shares have decreased by 50.7% and is now trading at $0.0035.

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) posted its quarterly earnings results on Thursday, May, 15th. The company reported ($8.46) earnings per share (EPS) for the quarter.

Petros Pharmaceuticals shares reverse split on Thursday, May 1st 2025.The 1-25 reverse split was announced on Tuesday, April 29th 2025. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 30th 2025. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Shares of PTPI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Petros Pharmaceuticals investors own include Predictive Oncology (POAI), Ford Motor (F), Wells Fargo & Company (WFC), Bank of America (BAC), Abbott Laboratories (ABT), Cricut (CRCT) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
5/15/2025
Today
8/20/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:PTPI
CIK
1815903
Fax
N/A
Employees
20
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($0.36)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$8.16 million
Net Margins
N/A
Pretax Margin
-117.50%
Return on Equity
-78.22%
Return on Assets
-23.50%

Debt

Debt-to-Equity Ratio
1.58
Current Ratio
0.85
Quick Ratio
0.74

Sales & Book Value

Annual Sales
$5.11 million
Price / Sales
0.02
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.04 per share
Price / Book
0.00

Miscellaneous

Outstanding Shares
31,160,000
Free Float
9,932,000
Market Cap
$109.06 thousand
Optionable
Not Optionable
Beta
1.88
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:PTPI) was last updated on 8/20/2026 by MarketBeat.com Staff.
From Our Partners